Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Spyre Therapeutics, Inc. (SYRE:NASDAQ), powered by AI.
Spyre Therapeutics, Inc. is currently trading at $83.41. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Spyre Therapeutics, Inc. on Alpha Lenz.
Spyre Therapeutics, Inc.'s P/E ratio is -34.4.
“Spyre Therapeutics, Inc. trades at a P/E of -34.4 (undervalued) with modest ROE of -25.2%.”
Ask for details →Spyre Therapeutics Inc. operates as a biopharmaceutical company focused on developing innovative therapies for autoimmune and inflammatory diseases. Its primary function is to research and bring to market novel medicines that target the underlying causes of these conditions, improving patient outcomes and quality of life. Spyre Therapeutics is actively involved in the biotechnology sector, where it leads efforts in drug discovery and development, leveraging cutting-edge technologies to identify new therapeutic pathways. The company's pipeline includes a range of biologic and small molecule drugs, each designed to address specific immune system dysregulations. In the financial market, Spyre Therapeutics plays a crucial role as a potential driver of growth within the biotech industry, attracting attention from investors interested in companies with promising research and development capabilities. The company's advancements can lead to significant healthcare impacts, offering progressive treatments in areas of significant unmet medical need.
“Spyre Therapeutics, Inc. trades at a P/E of -34.4 (undervalued) with modest ROE of -25.2%.”
Ask for details →Spyre Therapeutics, Inc. (ticker: SYRE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 65 employees. Market cap is $5.3B.
The current price is $83.41 with a P/E ratio of -34.43x and P/B of 7.47x.
ROE is -25.17%.